Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024).
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A. & Jemal, A. Colorectal cancer statistics, 2023. CA Cancer J. Clin. 73, 233–254 (2023).
Bull, C., Stoel, M. A., den Brok, M. H. & Adema, G. J. Sialic acids sweeten a tumor’s life. Cancer Res. 74, 3199–3204 (2014).
Pinho, S. S. & Reis, C. A. Glycosylation in cancer: mechanisms and clinical implications. Nat. Rev. Cancer 15, 540–555 (2015).
RodrIguez, E., Schetters, S. T. T. & van Kooyk, Y. The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nat. Rev. Immunol. 18, 204–211 (2018).
Stanczak, M. A. & Laubli, H. Siglec receptors as new immune checkpoints in cancer. Mol. Asp. Med. 90, 101112 (2023).
van Houtum, E. J. H., Bull, C., Cornelissen, L. A. M. & Adema, G. J. Siglec signaling in the tumor microenvironment. Front. Immunol. 12, 790317 (2021).
Angata, T. & Varki, A. Discovery, classification, evolution and diversity of Siglecs. Mol. Asp. Med. 90, 101117 (2023).
Crocker, P. R., Paulson, J. C. & Varki, A. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7, 255–266 (2007).
Beatson, R. et al. Cancer-associated hypersialylated MUC1 drives the differentiation of human monocytes into macrophages with a pathogenic phenotype. Commun. Biol. 3, 644 (2020).
Beatson, R. et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat. Immunol. 17, 1273–1281 (2016).
Haas, Q. et al. Siglec-9 regulates an effector memory CD8(+) T-cell subset that congregates in the melanoma tumor microenvironment. Cancer Immunol. Res. 7, 707–718 (2019).
Hudak, J. E., Canham, S. M. & Bertozzi, C. R. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat. Chem. Biol. 10, 69–75 (2014).
Jandus, C. et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J. Clin. Invest. 124, 1810–1820 (2014).
Rodriguez, E. et al. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. Nat. Commun. 12, 1270 (2021).
Stanczak, M. A. et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J. Clin. Invest. 128, 4912–4923 (2018).
Barkal, A. A. et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 572, 392–396 (2019).
Wu, Y. et al. Proximity labeling and genetic screening reveal that DSG2 is a counter receptor of Siglec-9 and suppresses macrophage phagocytosis. Adv. Sci. https://doi.org/10.1002/advs.202406654 (2025).
Huang, Z. et al. Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma. Cancer Gene Ther. 31, 427–438 (2024).
Takamiya, R., Ohtsubo, K., Takamatsu, S., Taniguchi, N. & Angata, T. The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-beta secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology 23, 178–187 (2013).
Wang, J. et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat. Med. 25, 656–666 (2019).
Wang, Y. et al. Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis. Proc. Natl Acad. Sci. USA 121, e2312929121 (2024).
Thiesler, H. et al. Proinflammatory macrophage activation by the polysialic acid-Siglec-16 axis is linked to increased survival of patients with glioblastoma. Clin. Cancer Res. 29, 2266–2279 (2023).
Angata, T., Hayakawa, T., Yamanaka, M., Varki, A. & Nakamura, M. Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates. FASEB J. 20, 1964–1973 (2006).
Ali, S. R. et al. Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus. J. Exp. Med. 211, 1231–1242 (2014).
Angata, T. et al. Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation. Cell Mol. Life Sci. 70, 3199–3210 (2013).
Yamanaka, M., Kato, Y., Angata, T. & Narimatsu, H. Deletion polymorphism of SIGLEC14 and its functional implications. Glycobiology 19, 841–846 (2009).
Zhang, L. et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell 181, 442–459.e429 (2020).
Cheng, S. et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184, 792–809.e723 (2021).
Rodrigues, E. et al. A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands. Nat. Commun. 11, 5091 (2020).
Eng, C. et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 20, 849–861 (2019).
Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
Yin, J. et al. SIGLEC11 promotes M2 macrophage polarization through AKT-mTOR signaling and facilitates the progression of gastric cancer. J. Immunother. Cancer 13, e010162 (2025).
Wieboldt, R. et al. Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2. Cell Mol. Immunol. 21, 495–509 (2024).
Xiao, R. et al. Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy. J. Hepatol. 80, 792–804 (2024).
Yin, S. et al. Siglec-G suppresses CD8(+) T cells responses through metabolic rewiring and can be targeted to enhance tumor immunotherapy. Adv. Sci. 11, e2403438 (2024).
Xiao, H., Woods, E. C., Vukojicic, P. & Bertozzi, C. R. Precision glycocalyx editing as a strategy for cancer immunotherapy. Proc. Natl Acad. Sci. USA 113, 10304–10309 (2016).
Gray, M. A. et al. Targeted glycan degradation potentiates the anticancer immune response in vivo. Nat. Chem. Biol. 16, 1376–1384 (2020).
Laubli, H. et al. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc. Natl Acad. Sci. USA 111, 14211–14216 (2014).
Friedman, D. J. et al. ST8Sia6 promotes tumor growth in mice by inhibiting immune responses. Cancer Immunol. Res. 9, 952–966 (2021).
Schmassmann, P. et al. Targeting the Siglec-sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma. Sci. Transl. Med. 15, eadf5302 (2023).
Stanczak, M. A. et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Sci. Transl. Med. 14, eabj1270 (2022).
Wu, J. et al. Targeted glycan degradation potentiates cellular immunotherapy for solid tumors. Proc. Natl Acad. Sci. USA 120, e2300366120 (2023).
Liu, Q., Xing, H., Xiong, M. & Zhang, X. B. Specifically editing cancer sialoglycans for enhanced in vivo immunotherapy through aptamer-enzyme chimeras. Angew. Chem. Int. Ed. Engl. 64, e202414327 (2025).
Sasaki, T., Brakebusch, C., Engel, J. & Timpl, R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J. 17, 1606–1613 (1998).
Muller, S. A. et al. Domain organization of Mac-2 binding protein and its oligomerization to linear and ring-like structures. J. Mol. Biol. 291, 801–813 (1999).
Laferte, S. & Loh, L. C. Characterization of a family of structurally related glycoproteins expressing beta 1-6-branched asparagine-linked oligosaccharides in human colon carcinoma cells. Biochem. J. 283, 193–201 (1992).
Iacobelli, S. et al. Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines. FEBS Lett. 319, 59–65 (1993).
Koths, K., Taylor, E., Halenbeck, R., Casipit, C. & Wang, A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J. Biol. Chem. 268, 14245–14249 (1993).
Laubli, H. et al. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs. J. Biol. Chem. 289, 33481–33491 (2014).
Cao, H. et al. SIGLEC16 encodes a DAP12-associated receptor expressed in macrophages that evolved from its inhibitory counterpart SIGLEC11 and has functional and non-functional alleles in humans. Eur. J. Immunol. 38, 2303–2315 (2008).
Schwarz, F. et al. Paired Siglec receptors generate opposite inflammatory responses to a human-specific pathogen. EMBO J. 36, 751–760 (2017).
Landig, C. S. et al. Evolution of the exclusively human pathogen Neisseria gonorrhoeae: human-specific engagement of immunoregulatory Siglecs. Evol. Appl. 12, 337–349 (2019).
Sun, J. et al. Exploring the cross-cancer effect of circulating proteins and discovering potential intervention targets for 13 site-specific cancers. J. Natl Cancer Inst. 116, 565–573 (2024).
Shi, H., Gao, L., Zhang, W. & Jiang, M. Identification and validation of a siglec-based and aging-related 9-gene signature for predicting prognosis in acute myeloid leukemia patients. BMC Bioinformatics 23, 284 (2022).
Huang, P. J., Low, P. Y., Wang, I., Hsu, S. D. & Angata, T. Soluble Siglec-14 glycan-recognition protein is generated by alternative splicing and suppresses myeloid inflammatory responses. J. Biol. Chem. 293, 19645–19658 (2018).
Ovsyannikova, I. G. et al. Genome-wide determinants of cellular immune responses to mumps vaccine. Vaccine 41, 6579–6588 (2023).
Shaw, B. C., Katsumata, Y., Simpson, J. F., Fardo, D. W. & Estus, S. Analysis of genetic variants associated with levels of immune modulating proteins for impact on Alzheimer’s disease risk reveal a potential role for SIGLEC14. Genes https://doi.org/10.3390/genes12071008 (2021).
Stampolidis, P., Ullrich, A. & Iacobelli, S. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, promotes oncogenic cellular events impeded by antibody intervention. Oncogene 34, 39–52 (2015).
Tinari, N. et al. Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int. J. Cancer 91, 167–172 (2001).
Becker, R. et al. Tumor stroma marker endosialin (Tem1) is a binding partner of metastasis-related protein Mac-2 BP/90K. FASEB J. 22, 3059–3067 (2008).
Lee, J. H. et al. Glycoprotein 90K, downregulated in advanced colorectal cancer tissues, interacts with CD9/CD82 and suppresses the Wnt/beta-catenin signal via ISGylation of beta-catenin. Gut 59, 907–917 (2010).
Nonaka, M. et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas. J. Biol. Chem. 286, 22403–22413 (2011).
Shahraz, A. et al. Anti-inflammatory activity of low molecular weight polysialic acid on human macrophages. Sci. Rep. 5, 16800 (2015).
Macauley, M. S., Crocker, P. R. & Paulson, J. C. Siglec-mediated regulation of immune cell function in disease. Nat. Rev. Immunol. 14, 653–666 (2014).
Tsubata, T. Siglec cis-ligands and their roles in the immune system. Glycobiology 33, 532–544 (2023).
Lin, S. Y., Schmidt, E. N., Takahashi-Yamashiro, K. & Macauley, M. S. Roles for Siglec-glycan interactions in regulating immune cells. Semin. Immunol. 77, 101925 (2024).
Gonzalez-Gil, A. & Schnaar, R. L. Siglec ligands. Cells https://doi.org/10.3390/cells10051260 (2021).
Fong, J. J. et al. Immunomodulatory activity of extracellular Hsp70 mediated via paired receptors Siglec-5 and Siglec-14. EMBO J. 34, 2775–2788 (2015).
Suematsu, R. et al. Identification of lipophilic ligands of Siglec5 and -14 that modulate innate immune responses. J. Biol. Chem. 294, 16776–16788 (2019).
Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57 (2009).
Sherman, B. T. et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 50, W216–W221 (2022).
Babicki, S. et al. Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res. 44, W147–W153 (2016).
Luh, H. T. et al. Does a negative correlation of heme oxygenase-1 with hematoma thickness in chronic subdural hematomas affect neovascularization and microvascular leakage? A retrospective study with preliminary validation. J. Neurosurg. 139, 536–543 (2023).
Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308(2013).